ADVM Stock Flops on Gene Therapy Data

ADVM is eyeing its biggest one-day loss in over four years

Deputy Editor
Sep 12, 2019 at 9:43 AM
facebook twitter linkedin

The shares of Adverum Biotechnologies Inc (NASDAQ:ADVM) are taking a serious nosedive today, down 32.8% at $8.07, after data from an early stage trial of the company's wet age-related macular degeneration (wet AMD) gene therapy treatment, ADVM-022, were poorly received. As a result, ADVM is trading back near its mid-May levels, eyeing its biggest one-day percentage drop in over four years. 

Taking a look at the charts, ADVM spent the better half of the year rallying toward a three-year high of $16.38, hit in mid-July. The stock has cooled since then, but managed to bounce off its 100-day moving average earlier this month. The equity has fallen well below this trendline today, though, and is roughly 50% off this two-year peak.

Analysts have been cautious on the stock, with only two calling it a "strong buy," compared to the four who say it's a "hold." Plus, the 12-month consensus price target of $9.75 is at a discount to last night's close. 

Short sellers have been piling on the drugmaker, too. In the last reporting period, short interest rose 24.7%. Now, the 9.31 million shares sold short represent 21.5% of the stock's available float. Plus, it would take 8.5 days to buy back all these bearish bets, at ADVM's average pace of trading. 

Bernie's Best Stock Bets for Summer 2021



Special Offers from Schaeffer's Trading Partners